曹熠熠, 李文波, 翁宇, 李佳, 陈畅, 庞华, 王政杰. 125I粒子植入联合抗PD-1治疗对小鼠Lewis肺癌的抑制作用研究[J]. 中国肿瘤临床, 2021, 48(5): 225-229. DOI: 10.3969/j.issn.1000-8179.2021.05.537
引用本文: 曹熠熠, 李文波, 翁宇, 李佳, 陈畅, 庞华, 王政杰. 125I粒子植入联合抗PD-1治疗对小鼠Lewis肺癌的抑制作用研究[J]. 中国肿瘤临床, 2021, 48(5): 225-229. DOI: 10.3969/j.issn.1000-8179.2021.05.537
shu
Yiyi Cao, Wenbo Li, Yu Weng, Jia Li, Chang Chen, Hua Pang, ZhengJie Wang. Effect of iodine-125 particle implantation combined with anti-PD-1 therapy on Lewis lung cancer in mice[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 48(5): 225-229. DOI: 10.3969/j.issn.1000-8179.2021.05.537
Citation: Yiyi Cao, Wenbo Li, Yu Weng, Jia Li, Chang Chen, Hua Pang, ZhengJie Wang. Effect of iodine-125 particle implantation combined with anti-PD-1 therapy on Lewis lung cancer in mice[J]. CHINESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 48(5): 225-229. DOI: 10.3969/j.issn.1000-8179.2021.05.537
shu

125I粒子植入联合抗PD-1治疗对小鼠Lewis肺癌的抑制作用研究

Effect of iodine-125 particle implantation combined with anti-PD-1 therapy on Lewis lung cancer in mice

    摘要
  • 摘要:
      目的  研究125I粒子植入对免疫微环境的影响，以及125I粒子植入联合抗程序性死亡受体-1（programmed cell death receptor-1，PD-1）治疗的抗肿瘤疗效。
      方法  在小鼠右后肢皮下注射Lewis肺癌（LLC）细胞构建肿瘤模型，利用流式细胞术分析125I粒子植入后PD-1、程序性死亡配体1（programmed death-ligand 1，PD-L1）、Treg细胞的表达。在小鼠右后肢（原位肿瘤）和左前肢（远位肿瘤）皮下注射LLC细胞，将小鼠随机分为PBS组、抗PD-1组、125I粒子植入组和联合治疗组。绘制肿瘤生长曲线，流式分析肿瘤浸润CD4+及CD8+T细胞比例。
      结果  125I粒子植入12天后PD-L1及PD-1表达上调（P < 0.01），Treg表达无显著性差异（P=0.196）。与其余各组相比，联合治疗组小鼠原位和远位肿瘤生长均受到明显抑制（均P < 0.05），肿瘤浸润CD8+T细胞比例显著增加（均P < 0.05）。
      结论  125I粒子植入联合抗PD-1治疗能激活机体抗肿瘤免疫，协同抑制小鼠LLC生长。

     

    Abstract:
      Objective  To study the effect of iodine-125 particle implantation (125I RPI) on the immune microenvironment and to determine the antitumor efficacy of 125I particles combined with anti-programmed cell death receptor 1(PD-1)therapy.
      Methods  Lewis lung cancer(LLC)cells were subcutaneously injected in mice to establish LLC mouse models.The expression of PD-1, PD-L1, and Treg cells was determined through flow cytometry following 125I RPI in these mice.LLC cells were subcutaneously injected into the right hind limb (primary tumor) and left flank (secondary tumor) of mice, and the mice were randomly assigned into PBS, anti-PD-1, 125I RPI, and combination therapy groups.The volumes of the primary and secondary tumors were measured, tumor growth curve was generated, and proportions of CD4+and CD8+T cells in the tumor tissue were analyzed via flow cytometry.
      Results  The expression of PD-1 and PD-L1 was significantly upregulated on day 12 after 125I RPI (P < 0.01);however, there was no significant difference in Treg expression (P=0.196).The growth of primary and secondary tumors was significantly inhibited (P < 0.05) and proportion of CD8+T cells was significantly increased (P < 0.05) in the combination therapy group compared to the other groups.
      Conclusions  125I RPI combined with anti-PD-1 therapy can activate anti-tumor immunity and inhibit the growth of LLC in mice

     

    • HTML全文
    • 参考文献(19)
    • 相关文章
    • 施引文献
  • 资源附件(0)

/

返回文章
返回